Checkpoint Therapeutics Inc (NASDAQ: CKPT) kicked off on Monday, down -4.15% from the previous trading day, before settling in for the closing price of $3.49. Over the past 52 weeks, CKPT has traded in a range of $1.38-$4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -47.67%. While this was happening, its average annual earnings per share was recorded 72.24%. With a float of $40.38 million, this company’s outstanding shares have now reached $45.10 million.
Let’s determine the extent of company efficiency that accounts for 23 employees. In terms of profitability, gross margin is -45168.08%, operating margin of -79817.02%, and the pretax margin is -98868.09%.
Checkpoint Therapeutics Inc (CKPT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Checkpoint Therapeutics Inc is 17.31%, while institutional ownership is 15.76%. The most recent insider transaction that took place on Dec 18 ’24, was worth 2,330,386. In this transaction CEO, President and Director of this company sold 602,167 shares at a rate of $3.87, taking the stock ownership to the 3,414,813 shares. Before that another transaction happened on Dec 19 ’24, when Company’s CEO, President and Director sold 220,230 for $3.38, making the entire transaction worth $744,377. This insider now owns 3,194,583 shares in total.
Checkpoint Therapeutics Inc (CKPT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.24% per share during the next fiscal year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Take a look at Checkpoint Therapeutics Inc’s (CKPT) current performance indicators. Last quarter, stock had a quick ratio of 0.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3271.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
Looking closely at Checkpoint Therapeutics Inc (NASDAQ: CKPT), its last 5-days average volume was 0.98 million, which is a jump from its year-to-date volume of 0.68 million. As of the previous 9 days, the stock’s Stochastic %D was 32.53%. Additionally, its Average True Range was 0.37.
During the past 100 days, Checkpoint Therapeutics Inc’s (CKPT) raw stochastic average was set at 52.87%, which indicates a significant increase from 25.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.11% in the past 14 days, which was higher than the 66.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.64, while its 200-day Moving Average is $2.47. However, in the short run, Checkpoint Therapeutics Inc’s stock first resistance to watch stands at $3.49. Second resistance stands at $3.62. The third major resistance level sits at $3.73. If the price goes on to break the first support level at $3.25, it is likely to go to the next support level at $3.14. Should the price break the second support level, the third support level stands at $3.01.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Key Stats
The company with the Market Capitalisation of 163.59 million has total of 48,833K Shares Outstanding. Its annual sales at the moment are 100 K in contrast with the sum of -51,850 K annual income. Company’s last quarter sales were recorded 40 K and last quarter income was -6,670 K.
